160 related articles for article (PubMed ID: 31484000)
1. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
Derakhshan F; Ionescu D; Cheung S; Churg A
Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000
[TBL] [Abstract][Full Text] [Related]
2. c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations.
Ren HZ; Cheung S; Churg A
Hum Pathol; 2020 Nov; 105():31-36. PubMed ID: 32916162
[TBL] [Abstract][Full Text] [Related]
3. UHRF1 Immunohistochemical Staining Separates Benign Reactive Spindle Cell Mesothelial Proliferations From Sarcomatoid Mesotheliomas.
Yang H; Cheung S; Churg A
Am J Surg Pathol; 2022 Jun; 46(6):840-845. PubMed ID: 34772842
[TBL] [Abstract][Full Text] [Related]
4. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
5. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
[TBL] [Abstract][Full Text] [Related]
6. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.
Hwang HC; Pyott S; Rodriguez S; Cindric A; Carr A; Michelsen C; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 May; 40(5):714-8. PubMed ID: 26900815
[TBL] [Abstract][Full Text] [Related]
7. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
[TBL] [Abstract][Full Text] [Related]
8. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
9. CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations.
Salisbury T; Churg A
Virchows Arch; 2021 Nov; 479(5):1047-1050. PubMed ID: 33721119
[TBL] [Abstract][Full Text] [Related]
10. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract][Full Text] [Related]
11. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
Berg KB; Churg A
Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203
[TBL] [Abstract][Full Text] [Related]
12. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
[TBL] [Abstract][Full Text] [Related]
14. β-catenin expression in benign and malignant pleural disorders.
Anani W; Bruggeman R; Zander DS
Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
[TBL] [Abstract][Full Text] [Related]
15. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
16. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
17. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
Naso JR; Tsuji S; Churg A
Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
[TBL] [Abstract][Full Text] [Related]
18. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
19. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples.
Monaco S; Mehrad M; Dacic S
Adv Anat Pathol; 2018 Jan; 25(1):24-30. PubMed ID: 29227332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
